Abbott’s booth will bring you new ways to achieve measurably better healthcare performance both in person and virtually with our personalized core diagnostics solutions consisting of Resourceful Advocates, Harmonized System and Intelligent Insights.
Traumatic brain injury (TBI) is a highly prevalent condition that contributes to the overcrowding of emergency departments (ED) worldwide, while also requiring a large proportion of frequently constrained ED resources. Traditional diagnostic tools for the effective triage of TBI patients predominantly rely on the clinical assessment and the use of neuroimaging tools such as computed tomography (CT). Wide use of head CT scans, however, have been associated with excessive and unnecessary radiation exposure. Moreover, experts consistently recommend measures to reduce CT scan use in the management of head injuries. Objective blood biomarkers that aid with identification of patients that do not need a CT scan can be a benefit for the management of mTBI. Join expert clinicians for this live discussion to understand tools to help improve patient management.
Tuesday, September 28 |
Hyatt Regency Atlanta
265 Peachtree St NE
Bring your questions to the Abbott booth and meet with our scientific experts on today’s most timely topics, including Traumatic Brain Injury (TBI) and COVID-19. We look forward to speaking with you.
|TUESDAY, SEPTEMBER 28|
|Creatinine||Analytical performance assessment of a newly formulated Creatinine Jaffe assay for Abbott’s Alinity c and ARCHITECT c Systems||Ali, S||A-149|
|Soluble Transferrin Receptor||Analytical Performance Assessment of a New Soluble Transferrin Receptor (sTfR) Assay on the Alinity c System||Soni, H||A-023|
|Total Bilirubin||Analytical Performance Assessment of a Newly Formulated REACH Compliant Total Bilirubin Assay on Abbott’s Alinity c and ARCHITECT c Systems||Hacker, D||A-158|
|Lactic Acid||Analytical Performance of a Newly Formulated REACH Compliant Lactic Acid Assay for Abbott’s Alinity c and ARCHITECT c Systems||Forsythe, C||A-009|
|Gamma-Glutamyl Transferase||Analytical Performance Assessment of a Newly Formulated REACH compliant gamma-Glutamyl Transferase Assay (GGT2) for Abbott’s Alinity c and ARCHITECT c Systems||Sheldon, J||A-142|
|IgG4 Subclass||A RUO monoclonal antibody assay for IgG4 Subclass detection on ARCHITECT c8000 clinical chemistry analyzer||Vaidya, S||A-045|
|Human Chorionic Gonadotropin (hCG) + Beta||Development and Analytical Performance of a new Research Use Only (RUO) hCG+β immunoassay for the Alinity i and the ARCHITECT i1000SR analyzers||Rajagopalan, V||A-080|
|Thyroid Function Tests||Establishment of Reference Intervals of Thyroid Function Tests (TFT) in Chinese Population on Abbott Alinity i System and Exploring the Possible Effect from Thyroid Autoantibodies||Chui, D.T.||A-198|
|Sigma Metrics of HbA1c Assay||Six Sigma Performance of the Alinity c HbA1c Assay||Berman, M||A-139|
|HIL on Alinity c System||Automated Sample Interference Indices on the Alinity c System||Berman, M||A-140|
|Lot-to-Lot Consistency of Cardiac Markers||Lot-to-Lot Reagent Variance Quantitation for Heart Failure Diagnosis and Monitoring Assays||Johnson, K||A-162|
|WEDNESDAY, SEPTEMBER 29|
|High Sensitivity HBsAg||Analytical Performance of a Highly-Sensitive HBsAg Assay and Its Early Detection of HBsAg in Seroconversion Panels||Wong, D||B-133|
|Acetaminophen||The New Clinical Chemistry Acetaminophen Assay for the ARCHITECT and Alinity Instruments||Alligrant, T||B-370|
|High Sensitivity HBsAg||Performance of High Sensitivity Hepatitis B Surface Antigen Quantitative Assay on Fully-automated Chemiluminescent Immunoassay Analyzer||Sasaki, N||B-134|
|Designer Benzodiazepines||Urine drug screening in the era of designer benzodiazepines: results of three immunoassay platforms and comparison to LC-QTOF-MS||Puzyrenko, A||B-285|
|Sigma Metrics||Sigma Metrics for Next Generation Clinical Chemistry Assays||Berman, M||B-213|
|Lot-to-Lot Consistency of COVID-19 Assays||Reagent Lot Consistency of Three SARS-CoV-2 Diagnostic Assays on Two Abbott Platforms||Johnson, K||B-096|
|Cocaine||Modernized standards for evaluation of Drugs of Abuse/Toxicology assays as demonstrated by the Cocaine assay on the Alinity c analyzer from Abbott Laboratories||Moore, M||B-269|
|SARS-CoV-2 IgG||Clinical and Analytical Assessment of a Spike-specific Quantitative IgG Assay for SARS-CoV-2||Maine, N||B-106|
|Pediatric Reference Range for Alinity Clinical Chemistry||Pediatric Reference Interval Verification for 28 Common Biochemical Assays on the Abbott Alinity System||Bohn, M.K.||B-237|
|Pediatric Reference Range for Alinity Endocrine Assays||Pediatric Reference Interval Verification for Endocrine and Fertility Hormone Assays on the Abbott Alinity System||Bohn, M.K.||B-238|
|Pediatric Reference Range for Alinity Cardiac Markers||Pediatric Reference Interval Establishment for Common Cardiac Markers on the Alinity ci System||Bohn, M.K.||B-239|
|Fentanyl||Evaluation of Concordance of Fentanyl Urine SEFRIA Immunoassay with LC-MS/MS Method||Pagaduan, J||B-267|
The UNIVANTS of healthcare excellence program is a prestigious global award program that was created by Abbott in partnership with leading healthcare organizations across the globe with a common vision to inspire and celebrate healthcare excellence. This program recognizes teams who collaborate across disciplines and transform healthcare delivery, and ultimately patient lives.Learn More
Change and risk are the new normal in healthcare due to staffing shortages, reimbursement cuts and more. With the Abbott Transformation System, we partner with you to create a strategic plan to help you realize operational and clinical care excellence. Visit the Abbott Transformation System area of the booth to learn how you can create impact in and beyond your lab.
Find the latest information in laboratory science, therapeutic areas and Abbott innovation.
Watch the webinar to hear from experts how you can realize the value within and beyond your laboratory walls with a TVO approach.
Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott. The website that you have requested also may not be optimised for your screen size.
Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.